The good news for Dyax
The bad news is that it wasn't the decision the company was looking for.
The FDA sent Dyax a complete response letter for DX-88, its hereditary angioedema (HAE) treatment. Like recent complete response letters to Genzyme
Doesn't sound so bad, does it? No, but it's not going to be a cake walk either.
Neither the REMS nor the manufacturing issue should be a major issue to overcome -- although some companies like Discovery Labs
In addition to the money issues, DX-88 has a lot of potential competition. ViroPharma
Dyax had the potential to be the Cinderella story of the March FDA decisions, but like all Cinderella stories, it was a long shot. Investors' best hope at this point is that the drug is on the market before the tournament starts next year.
Check out this Foolishness before you get back to watching B-ball:
More from The Motley Fool
Why Dyax Corp Rocketed 22% Higher in November
A buyout offer from a rival firm has Dyax shareholders seeing green.
Why Avago Technologies, Sanderson Farms, and Dyax Jumped Today
Even with the market in a near-free fall, these stocks managed to post solid gains. Find out why.
Here's Why Dyax Corp.'s Shares Jumped Today
Dyax's shares climbed by 12% today after the U.S. Federal Trade Commission ended the antitrust waiting period for the company's acquisition by Shire.